Investors Sell Shares of Ignyta (RXDX) on Strength (RXDX)

Traders sold shares of Ignyta Inc (NASDAQ:RXDX) on strength during trading on Friday. $49.29 million flowed into the stock on the tick-up and $115.66 million flowed out of the stock on the tick-down, for a money net flow of $66.37 million out of the stock. Of all stocks tracked, Ignyta had the 0th highest net out-flow for the day. Ignyta traded up $11.30 for the day and closed at $26.85

A number of analysts recently weighed in on RXDX shares. Cantor Fitzgerald set a $23.00 price target on shares of Ignyta and gave the stock a “buy” rating in a research report on Friday. Jefferies Group cut shares of Ignyta from a “buy” rating to a “hold” rating and set a $27.00 price target for the company. in a research report on Friday. SunTrust Banks started coverage on shares of Ignyta in a research report on Monday, November 20th. They set a “buy” rating for the company. Zacks Investment Research raised shares of Ignyta from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Tuesday, November 14th. Finally, Ladenburg Thalmann Financial Services upped their price target on shares of Ignyta from $20.25 to $31.00 in a research report on Wednesday, October 18th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $23.80.

The company has a market capitalization of $3,080.00, a P/E ratio of -9.91 and a beta of 206.06. The company has a debt-to-equity ratio of 0.34, a quick ratio of 6.07 and a current ratio of 6.07.

Ignyta (NASDAQ:RXDX) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.03. sell-side analysts expect that Ignyta Inc will post -2.27 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Ignyta by 10.4% during the first quarter. Vanguard Group Inc. now owns 1,228,177 shares of the biopharmaceutical company’s stock worth $10,562,000 after buying an additional 115,212 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Ignyta by 4.5% during the first quarter. Geode Capital Management LLC now owns 241,615 shares of the biopharmaceutical company’s stock worth $2,077,000 after buying an additional 10,471 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Ignyta by 6.9% during the first quarter. Dimensional Fund Advisors LP now owns 61,114 shares of the biopharmaceutical company’s stock worth $526,000 after buying an additional 3,946 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Ignyta by 58.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 91,645 shares of the biopharmaceutical company’s stock worth $789,000 after buying an additional 33,900 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY bought a new stake in Ignyta during the first quarter worth approximately $201,000. Institutional investors and hedge funds own 72.86% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Investors Sell Shares of Ignyta (RXDX) on Strength (RXDX)” was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/12/24/investors-sell-shares-of-ignyta-rxdx-on-strength-rxdx.html.

Ignyta Company Profile

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit